FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308382090> ?p ?o ?g. }

• W4308382090 abstract "<h3>Background</h3> The anti-CTLA-4 immuno-oncology therapy (IO) is limited in clinical efficacy due to its on-target toxicities. ADG116 is a fully human IgG1 monoclonal antibody that targets a unique and highly conserved epitope of CTLA-4. ADG116 enables a controlled T cell activation via partial CD80/86 ligand blockade and promotes strong Treg depletion in the tumor microenvironment via enhanced ADCC. In preclinical studies, ADG116 has been shown to be more potent and better tolerated than ipilimumab. We believe ADG116 can offer a better therapeutic window for this class of molecules, especially when combined with anti-PD-1 therapies. <h3>Methods</h3> ADG116 monotherapy [10 dose levels from 0.003 to 15 mg/kg (mpk)] and ADG116 (3 or 6 mpk) plus Tori (240 mg) combination therapy were administered Q3W intravenously. The primary endpoints are safety and tolerability; the secondary endpoints are PK, ORR per RECIST 1.1, and PFS. <h3>Results</h3> As of July 14, 2022, 45 patients (pts) were treated with ADG116 monotherapy, among which 3, 4, 6, 18, and 3 pts received 1, 3, 6, 10, and 15 mpk dose, respectively. The median age was 62; 62% received ≥3 prior lines of therapies, and 31% progressed after prior IO therapies. Only 1 DLT [Grade (G) 4 hyperglycemia] was observed (10 mpk), and MTD was not reached. Only 3 pts showed G3 or above treatment-related AEs (TRAEs); common TRAEs (>10%) consisted of diarrhea, pruritis, and fatigue. Disease control rate is 35% across doses of ³ 1 mg/kg (range 30-80%). An initial partial response was observed from a patient with Kaposi’s sarcoma (15 mpk). Dose expansion is ongoing at 10 mpk. Nine pts received ADG116/Tori combination therapy. The median age was 59; 11% received > 3 prior lines of therapies, and none had prior IO therapies. At 6 mpk ADG116/Tori, two pts developed DLTs (2/3; G3 myocarditis & G3 diarrhea). At 3 mpk ADG116/Tori, 1 DLT (1/6, G3 diarrhea) was observed, and five pts are still on treatment (2-5 cycles). One pt with recurrent platinum-refractory HNSCC has a confirmed complete response (CR) and is still on the study (cycle 5). Detailed safety and efficacy data from this study will be reported. <h3>Conclusions</h3> ADG116 monotherapy has cleared multiple dose levels including 15 mpk, a dose higher than any reported anti-CTLA-4 class agents in the repeat dose setting. ADG116 (3 mpk)/Tori (240mg) Q3W continuous dosing showed a manageable safety profile and encouraging efficacy including CR, supporting its further clinical evaluation. <h3>Acknowledgements</h3> We would like to acknowledge the editorial support from Ami Celeste Knoefler <h3>Trial Registration</h3> Clinical trial identification: NCT04501276 <h3>Ethics Approval</h3> The study obtained ethics approvals from the following Ethics Committee(s)/Institutional Review Board(s), the number/ID of the approval(s), 1. Macquarie University HREC; ID: 520-2166-4335-513 2. National Health Group Central IRB; ID: 2021/00824 3. Bellberry HREC; ID: 2020-04-397-AA 4. Salus IRB; ID: IORG0005674 5. CHAMG IRB; ID: 2021-10-064-001-HE001 6. Yonsei University Health System IRB; ID: 2021-2495-002/4-2021-1454 7. Samsung Medical Center IRB; ID: 2021-09-053-001 8. WCG IRB; ID: 2021-4916 All participants of this clinical study gave informed consent before taking part. <h3>Consent</h3> Written informed consent was obtained from patients for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal." @default.
• W4308382090 created "2022-11-11" @default.
• W4308382090 creator A5001621109 @default.
• W4308382090 creator A5006801199 @default.
• W4308382090 creator A5010102631 @default.
• W4308382090 creator A5010334212 @default.
• W4308382090 creator A5010965225 @default.
• W4308382090 creator A5015598872 @default.
• W4308382090 creator A5023064904 @default.
• W4308382090 creator A5034431014 @default.
• W4308382090 creator A5037942451 @default.
• W4308382090 creator A5045164151 @default.
• W4308382090 creator A5049870254 @default.
• W4308382090 creator A5051983148 @default.
• W4308382090 creator A5060992997 @default.
• W4308382090 creator A5066759908 @default.
• W4308382090 creator A5070888449 @default.
• W4308382090 creator A5071277762 @default.
• W4308382090 creator A5071787264 @default.
• W4308382090 creator A5072952875 @default.
• W4308382090 creator A5087491271 @default.
• W4308382090 date "2022-11-01" @default.
• W4308382090 modified "2023-09-26" @default.
• W4308382090 title "753 A phase 1b/2 study of a novel anti-CTLA-4 NEObody^TMADG116 monotherapy and in combination with toripalimab (Tori; Anti-PD-1 Antibody) in patients with advanced/metastatic solid tumors" @default.
• W4308382090 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0753" @default.
• W4308382090 hasPublicationYear "2022" @default.
• W4308382090 type Work @default.
• W4308382090 citedByCount "0" @default.
• W4308382090 crossrefType "proceedings-article" @default.
• W4308382090 hasAuthorship W4308382090A5001621109 @default.
• W4308382090 hasAuthorship W4308382090A5006801199 @default.
• W4308382090 hasAuthorship W4308382090A5010102631 @default.
• W4308382090 hasAuthorship W4308382090A5010334212 @default.
• W4308382090 hasAuthorship W4308382090A5010965225 @default.
• W4308382090 hasAuthorship W4308382090A5015598872 @default.
• W4308382090 hasAuthorship W4308382090A5023064904 @default.
• W4308382090 hasAuthorship W4308382090A5034431014 @default.
• W4308382090 hasAuthorship W4308382090A5037942451 @default.
• W4308382090 hasAuthorship W4308382090A5045164151 @default.
• W4308382090 hasAuthorship W4308382090A5049870254 @default.
• W4308382090 hasAuthorship W4308382090A5051983148 @default.
• W4308382090 hasAuthorship W4308382090A5060992997 @default.
• W4308382090 hasAuthorship W4308382090A5066759908 @default.
• W4308382090 hasAuthorship W4308382090A5070888449 @default.
• W4308382090 hasAuthorship W4308382090A5071277762 @default.
• W4308382090 hasAuthorship W4308382090A5071787264 @default.
• W4308382090 hasAuthorship W4308382090A5072952875 @default.
• W4308382090 hasAuthorship W4308382090A5087491271 @default.
• W4308382090 hasBestOaLocation W43083820901 @default.
• W4308382090 hasConcept C121608353 @default.
• W4308382090 hasConcept C126322002 @default.
• W4308382090 hasConcept C143998085 @default.
• W4308382090 hasConcept C159654299 @default.
• W4308382090 hasConcept C195616568 @default.
• W4308382090 hasConcept C197934379 @default.
• W4308382090 hasConcept C203014093 @default.
• W4308382090 hasConcept C203092338 @default.
• W4308382090 hasConcept C2776999253 @default.
• W4308382090 hasConcept C2777701055 @default.
• W4308382090 hasConcept C2778375690 @default.
• W4308382090 hasConcept C2781433595 @default.
• W4308382090 hasConcept C535046627 @default.
• W4308382090 hasConcept C542903549 @default.
• W4308382090 hasConcept C71924100 @default.
• W4308382090 hasConcept C98274493 @default.
• W4308382090 hasConceptScore W4308382090C121608353 @default.
• W4308382090 hasConceptScore W4308382090C126322002 @default.
• W4308382090 hasConceptScore W4308382090C143998085 @default.
• W4308382090 hasConceptScore W4308382090C159654299 @default.
• W4308382090 hasConceptScore W4308382090C195616568 @default.
• W4308382090 hasConceptScore W4308382090C197934379 @default.
• W4308382090 hasConceptScore W4308382090C203014093 @default.
• W4308382090 hasConceptScore W4308382090C203092338 @default.
• W4308382090 hasConceptScore W4308382090C2776999253 @default.
• W4308382090 hasConceptScore W4308382090C2777701055 @default.
• W4308382090 hasConceptScore W4308382090C2778375690 @default.
• W4308382090 hasConceptScore W4308382090C2781433595 @default.
• W4308382090 hasConceptScore W4308382090C535046627 @default.
• W4308382090 hasConceptScore W4308382090C542903549 @default.
• W4308382090 hasConceptScore W4308382090C71924100 @default.
• W4308382090 hasConceptScore W4308382090C98274493 @default.
• W4308382090 hasLocation W43083820901 @default.
• W4308382090 hasOpenAccess W4308382090 @default.
• W4308382090 hasPrimaryLocation W43083820901 @default.
• W4308382090 hasRelatedWork W195682249 @default.
• W4308382090 hasRelatedWork W1981898410 @default.
• W4308382090 hasRelatedWork W1992073661 @default.
• W4308382090 hasRelatedWork W2059923545 @default.
• W4308382090 hasRelatedWork W2063604066 @default.
• W4308382090 hasRelatedWork W2081460943 @default.
• W4308382090 hasRelatedWork W2091594406 @default.
• W4308382090 hasRelatedWork W2093009612 @default.
• W4308382090 hasRelatedWork W4252441337 @default.
• W4308382090 hasRelatedWork W991481628 @default.
• W4308382090 isParatext "false" @default.
• W4308382090 isRetracted "false" @default.
• W4308382090 workType "article" @default.